Up a level |
Giannoudis, Athina ORCID: 0000-0002-7200-1497, Malki, Mohammed Imad, Rudraraju, Bharath, Mohhamed, Hisham, Menon, Suraj, Liloglou, Triantafillos ORCID: 0000-0003-0460-1404, Ali, Simak, Carroll, Jason S and Palmieri, Carlo ORCID: 0000-0001-9496-2718
(2020)
Activating transcription factor-2 (ATF2) is a key determinant of resistance to endocrine treatment in an in vitro model of breast cancer.
Breast Cancer Research, 22 (1).
126-.
Rogerson, Connor, Sciacovelli, Marco ORCID: 0000-0003-2958-4292, Maddalena, Lucas A, Pouikli, Andromachi, Segarra-Mondejar, Marc, Valcarcel-Jimenez, Lorea, Schmidt, Christina, Yang, Ming, Ivanova, Elena, Kent, Joshua et al (show 5 more authors)
(2023)
FOXA2 controls the anti-oxidant response in FH-deficient cells.
CELL REPORTS, 42 (7).
112751-.
Hickey, Theresa E, Selth, Luke A, Chia, Kee Ming, Laven-Law, Geraldine, Milioli, Heloisa H, Roden, Daniel, Jindal, Shalini, Hui, Mun, Finlay-Schultz, Jessica, Ebrahimie, Esmaeil et al (show 14 more authors)
(2021)
The androgen receptor is a tumor suppressor in estrogen receptor-positive breast cancer.
NATURE MEDICINE, 27 (2).
310-+.
Giannoudis, Athina ORCID: 0000-0002-7200-1497, Malki, Mohammed I, Mohammed, Hisham, Rudraraju, Bharath, Menon, Suraj, Ali, Simak, Carroll, Jason S and Palmieri, Carlo ORCID: 0000-0001-9496-2718
(2020)
The regulatory role of activating transcription factor-2 (ATF2) in modulating tamoxifen resistance in estrogen-receptor positive breast cancer.
In: San Antonio Breast Cancer Symposium, San Antonio, USA.